

# China

Population 2018

1 428 million

Estimates of TB burden <sup>o</sup> , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	866 (740–1 000)	61 (52–70)
HIV-positive TB incidence	18 (9.8–28)	1.2 (0.69–2)
MDR/RR-TB incidence <sup>oo</sup>	66 (50–85)	4.6 (3.5–6)
HIV-negative TB mortality	37 (34–41)	2.6 (2.4–2.9)
HIV-positive TB mortality	2.4 (1.2–4)	0.17 (0.08–0.28)

## Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	7.1% (5.6–8.7)
Previously treated cases	21% (21–21)

## TB case notifications, 2018

Total new and relapse	795 245
- % tested with rapid diagnostics at time of diagnosis	15%
- % with known HIV status	60%
- % pulmonary	95%
- % bacteriologically confirmed <sup>ooo</sup>	37%
- % children aged 0-14 years	1%
- % women	31%
- % men	68%
Total cases notified	801 532

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	92% (79–110)
--	--------------

## TB patients facing catastrophic total costs

TB case fatality ratio (estimated mortality/estimated incidence), 2018	5% (4–6)
--	----------

## TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	7 935	2%
- on antiretroviral therapy	6 915	87%

## Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance <sup>ooo</sup>	
- New cases	58%
- Previously treated cases	100%
Laboratory-confirmed cases*	MDR/RR-TB: 14 636, XDR-TB: 430
Patients started on treatment**	MDR/RR-TB: 8 965, XDR-TB:
MDR/RR-TB cases tested for resistance to second-line drugs	

## Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	93%	764 701
Previously treated cases, excluding relapse, registered in 2017	83%	5 077
HIV-positive TB cases registered in 2017	87%	5 308
MDR/RR-TB cases started on second-line treatment in 2016	52%	5 405
XDR-TB cases started on second-line treatment in 2016		

## TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment

## TB financing, 2019

National TB budget (US\$ millions)	719
Funding source: 92% domestic, <1% international, 7% unfunded	

<sup>o</sup> Ranges represent uncertainty intervals

<sup>oo</sup> MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


<sup>ooo</sup> Calculated for pulmonary cases only

\* Includes cases with unknown previous TB treatment history

\*\* Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




Legend:  
■ Total TB incidence  
■ New and relapse TB cases notified  
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




Legend:  
■ HIV-negative TB mortality

## Notified cases by age group and sex, 2018




Legend:  
■ Females ■ Males  Incidence

## Treatment success rate (%)



Legend:  
■ New and relapse  
■ Retreatment, excluding relapse  
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB

## Total budget (US\$ millions)



Legend:  
■ Unfunded  
■ Funded internationally  
■ Funded domestically